|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500107285 |
|
最近更新日期: Date of Last Refreshed on: |
2025-08-07 16:27:31 |
|
注册时间: Date of Registration: |
2025-08-07 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于生成式人工智能的骨关节炎患者教育和自我管理的工具的临床应用:一项前瞻随机对照实验研究方案 |
|
Public title: |
Clinical Application of Generative AI-Based Tools for Patient Education and Self-Management in Osteoarthritis: A Prospective Randomized Controlled Trial Protocol |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于生成式人工智能的骨关节炎患者教育和自我管理的工具的临床应用:一项前瞻随机对照实验研究方案 |
|
Scientific title: |
Clinical Application of Generative AI-Based Tools for Patient Education and Self-Management in Osteoarthritis: A Prospective Randomized Controlled Trial Protocol |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王力 |
研究负责人: |
李箭 |
|
Applicant: |
Wang Li |
Study leader: |
Li Jian |
|
申请注册联系人电话: Applicant telephone: |
+86 181 6119 0316 |
研究负责人电话: Study leader's telephone: |
+86 189 8060 1388 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wangli1@stu.scu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
lijian_sportsmed@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市武侯区国学巷37号 |
研究负责人通讯地址: |
四川省成都市武侯区国学巷37号 |
|
Applicant address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan |
Study leader's address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan |
|
申请注册联系人邮政编码: Applicant postcode: |
610041 |
研究负责人邮政编码: Study leader's postcode: |
610041 |
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital, Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital, Sichuan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025年审(1165)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院生物医学伦理审查委员会 |
||
|
Name of the ethic committee: |
Biomedical Ethics Review Committee of West China Hospital, Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-07-16 00:00:00 |
||
|
伦理委员会联系人: |
李娜 |
||
|
Contact Name of the ethic committee: |
Li Na |
||
|
伦理委员会联系地址: |
四川省成都市武侯区国学巷37号 |
||
|
Contact Address of the ethic committee: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8542 2654 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital, Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市武侯区国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
ZYGD21005 运动医学关键性生物学诊疗技术的基础及临床转化研究 |
||||||||||||||||||||||
|
Source(s) of funding: |
Basic and Clinical Translational Research on Key Biological Diagnosis and Treatment Technologies in Sports Medicine (ZYGD21005) |
||||||||||||||||||||||
|
Target disease: |
Osteoarthritis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
基于检索生成增强和微调训练专用于骨关节炎患者教育和自我管理的垂直大模型并验证其临床有效性(能否改善膝骨关节炎患者的健康素养和功能疼痛的结局评分) |
||||||||||||||||||||||
|
Objectives of Study: |
Based on retrieval, enhancement and fine-tuning training of vertical large models dedicated to the education and self-management of osteoarthritis patients, and verifying its clinical effectiveness (whether it can improve the outcome score of health literacy and functional pain in patients with knee osteoarthritis) |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.经门诊首次确诊膝骨关节炎的患者(依照中华医学会骨科学分会制定的诊断标准,主要包括以下几条: 1)近 1 个月内反复的膝关节疼痛; 2)站立位或者负重位的 X 线片显示关节间隙变窄、软骨下骨硬化或囊性变、关节边缘骨赘形成; 3)年龄>50岁; 4)晨起时关节僵硬时间在 30 分钟以内; 5)关节活动时有骨摩擦音或者骨摩擦感。 满足以上诊断标准的第一条以及余下四条中的任意两条,即可诊断为膝关节骨性关节炎。); 2.选择进行保守治疗的患者 ; 3.愿意参加本临床试验并接受随访。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Patients with a first-time outpatient diagnosis of knee osteoarthritis (KOA), based on the latest diagnostic criteria issued by the Chinese Orthopaedic Association, which include: 1) Recurrent knee pain in the past month 2) X-ray findings in standing or weight-bearing position showing joint space narrowing.subchondral sclerosis or cystic changes, or osteophyte formation at the joint marginsAge over 50 years; 3) Morning stiffness lasting no more than 30 minutes; 4) Crepitus or a grating sensation during joint movement. 5) A diagnosis of KOA is established when the first criterion and any two of the remaining four are met. 2. Patients who choose to undergo conservative (non-surgical) treatment. 3. Patients who are willing to participate in this clinical trial and agree to follow-up assessments. |
||||||||||||||||||||||
|
排除标准: |
1.选择进行全膝关节置换或关节镜手术; 2.干预期间有其他手术计划的患者; 3. 膝关节骨性关节炎合并任何感染、炎症、自身免疫性疾病或骨折。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients who choose to undergo total knee arthroplasty or arthroscopic surgery; 2. Patients who have plans for other surgical procedures during the intervention period; 3. Patients with KOA complicated by infections, inflammatory or autoimmune diseases, or fractures. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-28 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-08-12 00:00:00 至 To 2025-09-10 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
对前 20 位受试者,使用 python 的 random 库进行完全随机化: 生成一个 1 到 2 之间的随机整数 import random random_number = random.randint(1, 2) print(random_number) 纳入 20 位患者后,实时进行 t 检验确保主要混杂因素的平衡(年龄,BMI,性别比例, 受教育程度的比例(初中及以下 高中 大专及以上),优先满足年龄,BMI 和性别): 代码框架如下: for each participant: simulate adding to treatment and control group respectively for each simulation: compute t-test p-values for age, bmi if both p-values > 0.05: calculate imbalance score pick the one with lowest imbalance and p > 0.05 if both p-values < 0.05: pick the one with minimal imbalance (with random noise) |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
For the first 20 subjects, use the `random` library in Python for complete randomization: Generate a random integer between 1 and 2 python import random random_number = random.randint(1, 2) print(random_number) After enrolling 20 patients, perform t - tests in real - time to ensure the balance of major confounding factors (age, BMI, gender ratio, and the proportion of educational attainment (junior high school or below, high school, junior college or above), with priority given to age, BMI, and gender): The code framework is as follows: for each participant: simulate adding to treatment and control group respectively for each simulation: compute t - test p - values for age, bmi if both p - values > 0.05: calculate imbalance score pick the one with lowest imbalance and p > 0.05 if both p - values < 0.05: pick the one with minimal imbalance (with random noise) |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
前瞻性、随机、开放标签、盲终点(PROBE)试验,即对评估者设盲 |
|
Blinding: |
Prospective, randomized, open-label, blinded endpoint (PROBE) trial, which means blinding the evaluators |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
https://figshare.com/,在试验结束后6个月内上传 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
https://figshare.com/,Upload within 6 months of the end of the trial |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用华西医院的数据采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Adopt data collection and management system of West China Hospital |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |